Kohji Takemura, MD· @KohjiToncol · X·· 2 days agoScore70
Body
KEYNOTE-866: Negative for EFS.
ENERGIZE: Negative for EFS.
→ What made the difference between these trials and NIAGARA?
#ESMO26
98 views · 1 like · 1 repost · 0 replies
Conference abstracts
4735Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.orgSource: Kohji Takemura, MD · x.com